We are live on ! Find out more
RLMD icon

Relmada Therapeutics
RLMD

79 hedge funds and large institutions have $40.7M invested in Relmada Therapeutics in 2024 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 15 increasing their positions, 31 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

183% more call options, than puts

Call options by funds: $568K | Put options by funds: $201K

2.51% less ownership

Funds ownership: 47.44% → 44.93% (-2.5%)

15% less funds holding

Funds holding: 93 → 79 (-14)

39% less capital invested

Capital invested by funds: $66.5M → $40.7M (-$25.8M)

52% less repeat investments, than reductions

Existing positions increased: 15 | Existing positions reduced: 31

68% less first-time investments, than exits

New positions opened: 6 | Existing positions closed: 19

Holders
79
Holders Change
-14
Holders Change %
-15.05%
% of All Funds
1.14%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
15
Reduced
31
Closed
19
Calls
$568K
Puts
$201K
Net Calls
+$367K
Net Calls Change
+$62K

Top Buyers

1
Franklin Resources
Franklin Resources
California
+$1.38M
2
TCM
Tang Capital Management
California
+$859K
3
JP Morgan Chase
JP Morgan Chase
New York
+$639K
4
Renaissance Technologies
Renaissance Technologies
New York
+$195K
5
ACM
ADAR1 Capital Management
Texas
+$181K

Top Sellers

1
Millennium Management
Millennium Management
New York
-$1M
2
OM
Opaleye Management
Massachusetts
-$575K
3
Goldman Sachs
Goldman Sachs
New York
-$550K
4
Jane Street
Jane Street
New York
-$498K
5
GIM
Guild Investment Management
California
-$425K
Name Holding Trade Value Shares
Change 		Change in
Stake
SCM
26
Silverarc Capital Management
Massachusetts
$298K – – –
Federated Hermes
27
Federated Hermes
Pennsylvania
$288K – – –
AI
28
AdvisorShares Investments
Maryland
$276K +$72.3K +19,975 +29%
Fidelity Investments
29
Fidelity Investments
Massachusetts
$271K +$23.6K +6,512 +8%
Renaissance Technologies
30
Renaissance Technologies
New York
$266K +$195K +53,767 +154%
Citadel Advisors
31
Citadel Advisors
Florida
$253K +$49.8K +13,769 +20%
Northern Trust
32
Northern Trust
Illinois
$237K -$7.5K -2,074 -3%
Jacobs Levy Equity Management
33
Jacobs Levy Equity Management
New Jersey
$237K -$170K -47,023 -37%
AW
34
Apricus Wealth
South Carolina
$237K – – –
GIM
35
Guild Investment Management
California
$221K -$425K -117,404 -61%
Dimensional Fund Advisors
36
Dimensional Fund Advisors
Texas
$220K -$1.52K -420 -0.6%
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
$204K +$151K +41,777 +158%
Millennium Management
38
Millennium Management
New York
$193K -$1M -277,093 -81%
Citigroup
39
Citigroup
New York
$189K -$220K -60,862 -49%
ACM
40
ADAR1 Capital Management
Texas
$152K +$181K +50,000 +8,319%
Morgan Stanley
41
Morgan Stanley
New York
$139K -$269K -74,338 -62%
Simplex Trading
42
Simplex Trading
Illinois
$123K -$19.7K -5,443 -12%
IC
43
Ikarian Capital
Texas
$121K – – –
Jane Street
44
Jane Street
New York
$112K -$498K -137,753 -79%
SEI Investments
45
SEI Investments
Pennsylvania
$109K – – –
Squarepoint
46
Squarepoint
New York
$106K -$158K -43,588 -55%
AG
47
AlTi Global
New York
$95.9K – – –
American Century Companies
48
American Century Companies
Missouri
$94.9K +$14.6K +4,027 +15%
WIA
49
World Investment Advisors
California
$92.1K – – –
HKAM
50
Horizon Kinetics Asset Management
New York
$90K – – –
1
2
3 4

RLMD Hedge Fund Activity: Q2 2024 in Review

79 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Relmada Therapeutics (RLMD) for Q2 2024, worth a combined $40.7M — down 39% from $66.5M a quarter earlier.

Sellers outnumbered buyers: 19 funds closed out of RLMD and 6 opened new positions — a net loss of 13 holders — while 31 trimmed existing stakes and 15 added.

The largest buyer was Franklin Resources, adding an estimated $1.38M. The largest seller was Millennium Management, cutting an estimated $1M.

  • 79 institutional investors held Relmada Therapeutics (RLMD) as of Q2 2024, down from 93 in Q1 2024.
  • Funds reported $40.7M of Relmada Therapeutics stock for Q2 2024, down 39% quarter-over-quarter.
  • 6 funds opened new Relmada Therapeutics positions in Q2 2024 and 19 closed out, a net change of -13 holders.
  • The largest Relmada Therapeutics buyer in Q2 2024 was Franklin Resources, an estimated $1.38M added.
  • The largest Relmada Therapeutics seller in Q2 2024 was Millennium Management, an estimated $1M sold.

Based on aggregated 13F filings for Q2 2024.